Literature DB >> 24550101

Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.

Anish Babu1, Amanda K Templeton, Anupama Munshi, Rajagopal Ramesh.   

Abstract

Nanotechnology has enabled the development of novel therapeutic and diagnostic strategies, such as advances in targeted drug delivery systems, versatile molecular imaging modalities, stimulus responsive components for fabrication, and potential theranostic agents in cancer therapy. Nanoparticle modifications such as conjugation with polyethylene glycol have been used to increase the duration of nanoparticles in blood circulation and reduce renal clearance rates. Such modifications to nanoparticle fabrication are the initial steps toward clinical translation of nanoparticles. Additionally, the development of targeted drug delivery systems has substantially contributed to the therapeutic efficacy of anti-cancer drugs and cancer gene therapies compared with nontargeted conventional delivery systems. Although multifunctional nanoparticles offer numerous advantages, their complex nature imparts challenges in reproducibility and concerns of toxicity. A thorough understanding of the biological behavior of nanoparticle systems is strongly warranted prior to testing such systems in a clinical setting. Translation of novel nanodrug delivery systems from the bench to the bedside will require a collective approach. The present review focuses on recent research efforts citing relevant examples of advanced nanodrug delivery and imaging systems developed for cancer therapy. Additionally, this review highlights the newest technologies such as microfluidics and biomimetics that can aid in the development and speedy translation of nanodrug delivery systems to the clinic.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24550101      PMCID: PMC4037475          DOI: 10.1208/s12249-014-0089-8

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  109 in total

1.  Toxicity of cationic liposome-DNA complex in lung isografts.

Authors:  I Nagahiro; B N Mora; C H Boasquevisque; R K Scheule; G A Patterson
Journal:  Transplantation       Date:  2000-05-15       Impact factor: 4.939

2.  Microfluidic assisted self-assembly of chitosan based nanoparticles as drug delivery agents.

Authors:  Fatemeh Sadat Majedi; Mohammad Mahdi Hasani-Sadrabadi; Shahriar Hojjati Emami; Mohammad Ali Shokrgozar; Jules John VanDersarl; Erfan Dashtimoghadam; Arnaud Bertsch; Philippe Renaud
Journal:  Lab Chip       Date:  2012-11-30       Impact factor: 6.799

3.  Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.

Authors:  Lilach Agemy; Venkata R Kotamraju; Dinorah Friedmann-Morvinski; Shweta Sharma; Kazuki N Sugahara; Erkki Ruoslahti
Journal:  Mol Ther       Date:  2013-08-20       Impact factor: 11.454

4.  Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics.

Authors:  F Dosio; S Arpicco; P Brusa; B Stella; L Cattel
Journal:  J Control Release       Date:  2001-09-11       Impact factor: 9.776

5.  CO2 gas induced drug release from pH-sensitive liposome to circumvent doxorubicin resistant cells.

Authors:  Juan Liu; Huili Ma; Tuo Wei; Xing-Jie Liang
Journal:  Chem Commun (Camb)       Date:  2012-04-12       Impact factor: 6.222

6.  Local drug delivery with a self-contained, programmable, microfluidic system.

Authors:  J Fiering; M J Mescher; E E Leary Swan; M E Holmboe; B A Murphy; Z Chen; M Peppi; W F Sewell; M J McKenna; S G Kujawa; J T Borenstein
Journal:  Biomed Microdevices       Date:  2009-06       Impact factor: 2.838

7.  Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.

Authors:  Minghuang Hong; Saijie Zhu; Yanyan Jiang; Guotao Tang; Chang Sun; Chao Fang; Bin Shi; Yuanying Pei
Journal:  J Control Release       Date:  2009-09-04       Impact factor: 9.776

8.  Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro.

Authors:  I Ahmad; T M Allen
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

Review 9.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

10.  pH-responsive drug delivery of chitosan nanoparticles as Tamoxifen carriers for effective anti-tumor activity in breast cancer cells.

Authors:  R Vivek; V Nipun Babu; R Thangam; K S Subramanian; S Kannan
Journal:  Colloids Surf B Biointerfaces       Date:  2013-05-22       Impact factor: 5.268

View more
  16 in total

1.  Translational application of nano delivery systems: emerging cancer therapy.

Authors:  Mahavir B Chougule; Chalet Tan
Journal:  AAPS PharmSciTech       Date:  2014-12-31       Impact factor: 3.246

Review 2.  Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics.

Authors:  Elham Hatami; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-05-31       Impact factor: 10.680

Review 3.  Polymersome-based drug-delivery strategies for cancer therapeutics.

Authors:  Tayebeh Anajafi; Sanku Mallik
Journal:  Ther Deliv       Date:  2015

Review 4.  Kinetics of Nanomedicine in Tumor Spheroid as an In Vitro Model System for Efficient Tumor-Targeted Drug Delivery With Insights From Mathematical Models.

Authors:  Sayoni Maitra Roy; Vrinda Garg; Sourav Barman; Chitrita Ghosh; Amit Ranjan Maity; Surya K Ghosh
Journal:  Front Bioeng Biotechnol       Date:  2021-12-01

5.  A library of aminoglycoside-derived lipopolymer nanoparticles for delivery of small molecules and nucleic acids.

Authors:  Sudhakar Godeshala; Bhavani Miryala; Subhadeep Dutta; Matthew D Christensen; Purbasha Nandi; Po-Lin Chiu; Kaushal Rege
Journal:  J Mater Chem B       Date:  2020-09-30       Impact factor: 6.331

Review 6.  Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.

Authors:  Mostafa Akbarzadeh Khiavi; Azam Safary; Jaleh Barar; Amir Ajoolabady; Mohammad Hossein Somi; Yadollah Omidi
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

Review 7.  Nanopharmaceuticals (part 1): products on the market.

Authors:  Volkmar Weissig; Tracy K Pettinger; Nicole Murdock
Journal:  Int J Nanomedicine       Date:  2014-09-15

8.  Differences in predictions of ODE models of tumor growth: a cautionary example.

Authors:  Hope Murphy; Hana Jaafari; Hana M Dobrovolny
Journal:  BMC Cancer       Date:  2016-02-26       Impact factor: 4.430

9.  Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells.

Authors:  Akhil Srivastava; Narsireddy Amreddy; Anish Babu; Janani Panneerselvam; Meghna Mehta; Ranganayaki Muralidharan; Allshine Chen; Yan Daniel Zhao; Mohammad Razaq; Natascha Riedinger; Hogyoung Kim; Shaorong Liu; Si Wu; Asim B Abdel-Mageed; Anupama Munshi; Rajagopal Ramesh
Journal:  Sci Rep       Date:  2016-12-12       Impact factor: 4.379

10.  Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts.

Authors:  Stephanie J Blocker; Kirk A Douglas; Lisa Anne Polin; Helen Lee; Bart S Hendriks; Enxhi Lalo; Wei Chen; Anthony F Shields
Journal:  Theranostics       Date:  2017-09-26       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.